Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Thomas Martin, MD
University of California, San Francisco
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- University of California, San Francisco
San Francisco, California, United States
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Jan 2015
- Primary completion
- 31 Dec 2025
- Completion
- 31 Dec 2025
- Last update posted
- 11 Jun 2026
- Registered enrollment
- 83
- Registry id
- NCT02332850
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.